Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA ANDA Full Approvals Down In FY 2003, Total Applications Increase

Executive Summary

The number of full generic drug approvals dropped slightly in fiscal 2003 to 284, compared to 296 in fiscal 2002

You may also be interested in...



FDA Office Of Generic Drugs Adding Fourth Team To Handle Increased ANDAs

The Center for Drug Evaluation & Research Office of Generic Drugs is adding a fourth team within the Division of Bioequivalence to handle an increase in ANDA submissions, FDA said at a Drug Information Association meeting March 1 in Bethesda, Md

FDA Office Of Generic Drugs Adding Fourth Team To Handle Increased ANDAs

The Center for Drug Evaluation & Research Office of Generic Drugs is adding a fourth team within the Division of Bioequivalence to handle an increase in ANDA submissions, FDA said at a Drug Information Association meeting March 1 in Bethesda, Md

FDA Drug Center Would Lose 44 FTEs Under Fiscal 2005 Budget Request

FDA's fiscal 2005 budget request includes a reduction of 44 full-time equivalent positions in the Center for Drug Evaluation & Research

Related Content

UsernamePublicRestriction

Register

LL033172

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel